摘要
目的:探讨苏黄止咳胶囊辅助治疗肺炎支原体(MP)感染伴咳嗽变异性哮喘(CVA)的效果及对白细胞介素-4(IL-4)、γ干扰素(IFN-γ)、C反应蛋白(CRP)的影响。方法:纳入2022年1月—2023年12月瑞金市妇幼保健院收治的80例MP感染伴CVA患者,随机将其分为西药组与中药组,各40例。西药组给予阿奇霉素、布地奈德联合特布他林雾化吸入等常规治疗,中药组在西药组治疗基础上加服苏黄止咳胶囊。比较两组临床疗效、症状体征持续时间、治疗前后肺功能[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、呼气流量峰值(PEF)]、气道重塑指标[气道腔面积(AI)、气道壁厚度(T)、气道管壁面积(WA)]、炎症因子(IL-4、IFN-γ、CRP)、不良反应及CVA复发情况。结果:中药组总有效率(95.00%)高于西药组(80.00%),差异有统计学意义(P<0.05);中药组发热、咳嗽、咳痰、喘憋、肺部啰音持续时间均短于西药组,差异均有统计学意义(P<0.05);治疗后,两组FVC、FEV_(1)、PEF、IFN-γ均升高,且中药组均高于西药组,差异均有统计学意义(P<0.05);治疗后,两组AI、T、WA均减小,中药组均小于对照组,IL-4、CRP均降低,中药组均低于西药组,差异均有统计学意义(P<0.05);中药组和西药组不良反应发生率(10.00% vs 7.50%)、哮喘复发率(3.70% vs 8.33%)比较,差异均无统计学意义(P>0.05)。结论:苏黄止咳胶囊辅助治疗MP感染伴CVA效果显著,可缓解临床症状,改善机体肺功能,减轻气道重塑,抑制炎症反应,且安全性较高。
Objective:To investigate the effect of Suhuang Zhike Capsules in the adjuvant treatment of Mycoplasma pneumoniae(MP)infection with cough variant asthma(CVA)and its influence on interleukin-4(IL-4),interferonγ(IFN-γ)and C reactive protein(CRP).Method:A total of 80 patients with MP infection and CVA admitted to Ruijin Maternal and Child Health Care Hospital from January 2022 to December 2023 were included and randomly divided into western medicine group and Chinese medicine group,with 40 cases in each group.The western medicine group was given Azithromycin,Budesonide combined with Terbutaline atomization inhalation and other conventional treatment,and the Chinese medicine group was given Suhuang Zhike Capsules on the basis of the western medicine group.The clinical efficacy,duration of symptoms and signs,pulmonary function[forced vital capacity(FVC),forced expiratory volume in one second(FEV_(1)),peak expiratory flow(PEF)],airway remodeling indicators[airway cavity area(AI),airway wall thickness(T),airway wall area(WA)]and inflammatory factors[interleukin-4(IL-4),IFN-γ,C reactive protein(CRP)]before and after treatment,and adverse reactions and CVA recurrence were compared between the two groups.Result:The total effective rate of Chinese medicine group(95.00%)was higher than that of western medicine group(80.00%),the difference was statistically significant(P<0.05).The duration of fever,cough,expectoration,choking and pulmonary rale in Chinese medicine group were shorter than those in western medicine group,the differences were statistically significant(P<0.05).After treatment,FVC,FEV_(1),PEF,IFN-γwere increased in both groups,and those in the Chinese medicine group were higher than those in the western medicine group,the differences were statistically significant(P<0.05).After treatment,AI,T and WA were decreased in both groups,those in the Chinese medicine group were lower than those in the control group,IL-4 and CRP were decreased,and those in the Chinese medicine group were lower than those in the western medicine group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions(10.00%vs 7.50%)and CVA recurrence(3.70%vs 8.33%)between the the Chinese medicine group and the western medicine group(P>0.05).Conclusion:Suhuang Zhike Capsules has a significant effect in the adjuvant treatment of MP infection with CVA,which can alleviate clinical symptoms,improve lung function,reduce airway remodeling,inhibit inflammatory response,and has high safety.
作者
陈丹
钟起华
CHEN Dan;ZHONG Qihua(Department of Internal Medicine,Ruijin Maternal and Child Health Care Hospital,Ruijin 342500,China;不详)
出处
《中国医学创新》
CAS
2024年第26期62-66,共5页
Medical Innovation of China
基金
赣州市2022年指导性科技计划项目(GZ2022ZSF654)。
作者简介
通信作者:陈丹。
